Literature DB >> 9349726

Molecular characterization of the cyclin-dependent kinase inhibitor p27 promoter.

Y Zhang1, S C Lin.   

Abstract

p27Kip1 is a member of the family of cyclin-dependent kinase inhibitors (CKIs), which play critical roles in the regulation of cell cycle. To study the transcriptional regulation that controls the expression of p27, we have isolated the p27 promoter, defined its transcription initiation site, and performed various analyses for sequences upstream to 3 kb. Transient transfection assays using fusion reporters containing progressively truncated p27 promoter fragments showed that a region of 170 bp upstream of the start site is sufficient for maximal transcription activity. Detailed sequence analysis of this 170 bp region identified several GC-rich segments, putative sites of the transcription factor Sp1. Footprinting experiments revealed two Sp1-protected boxes, named BoxI and BoxII, which are located at positions -133 to -117 and -87 to -72, respectively. Binding of Sp1 to the two boxes was further demonstrated by gel mobility shift assays and supershift assays. Co-transfection studies in Drosophila Schneider line 2 cells showed that Sp1 indeed activates the p27 promoter constructs that harbor one or both of the GC-rich sequences. Furthermore, the GC-rich sequences could confer Sp1-dependent transactivation to a heterologous prolactin minimal promoter. Mutations in the GC-rich sequences abolished both binding and transactivation by Sp1. Taken together, our data strongly show that the p27 promoter is activated by the ubiquitously expressed transcription factor Sp1, which may provide a molecular mechanism for the constitutive nature of p27 transcription.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9349726     DOI: 10.1016/s0167-4781(97)00063-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  The major transcription initiation site of the p27Kip1 gene is conserved in human and mouse and produces a long 5'-UTR.

Authors:  J Coleman; M Hawkinson; R Miskimins; W K Miskimins
Journal:  BMC Mol Biol       Date:  2001-10-11       Impact factor: 2.946

2.  Control of cyclin-dependent kinase inhibitor p27 expression by cap-independent translation.

Authors:  W K Miskimins; G Wang; M Hawkinson; R Miskimins
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

3.  Deregulated expression of the homeobox gene Cux-1 in transgenic mice results in downregulation of p27(kip1) expression during nephrogenesis, glomerular abnormalities, and multiorgan hyperplasia.

Authors:  Aric W Ledford; Jennifer G Brantley; Gabor Kemeny; Tonia L Foreman; Susan E Quaggin; Peter Igarashi; Stephanie M Oberhaus; Marianna Rodova; James P Calvet; Gregory B Vanden Heuvel
Journal:  Dev Biol       Date:  2002-05-01       Impact factor: 3.582

4.  Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide.

Authors:  Clement G Yedjou; Paul B Tchounwou
Journal:  Mol Cell Biochem       Date:  2009-05-15       Impact factor: 3.396

5.  The homeodomain protein Cux1 interacts with Grg4 to repress p27 kip1 expression during kidney development.

Authors:  Madhulika Sharma; Jennifer G Brantley; Dianne Vassmer; Gaurav Chaturvedi; Jennifer Baas; Gregory B Vanden Heuvel
Journal:  Gene       Date:  2009-03-28       Impact factor: 3.688

6.  Differential regulation of p27(Kip1) expression by mitogenic and hypertrophic factors: Involvement of transcriptional and posttranscriptional mechanisms.

Authors:  M J Servant; P Coulombe; B Turgeon; S Meloche
Journal:  J Cell Biol       Date:  2000-02-07       Impact factor: 10.539

7.  Everolimus (RAD001) inhibits the proliferation of rat vascular smooth muscle cells by up-regulating the activity of the p27/kip1 gene promoter.

Authors:  Boli Ran; Minfeng Li; Yeqing Li; Yang Lin; Weimin Liu; Qiulin Luo; Yongxin Fu; Qianmei Tang; Ya Yang; Yunfei Pu
Journal:  Anatol J Cardiol       Date:  2016-05-09       Impact factor: 1.596

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.